Mounjaro vs Zepbound vs compounded tirzepatide: what's actually different

Tirzepatide runs into the same three-way confusion as semaglutide: two FDA-approved brand names and a compounded cash-pay version, all built around the same active drug. The differences matter more than the shared name suggests.

Same molecule, two approved uses

Mounjaro and Zepbound are both FDA-approved tirzepatide products from the same manufacturer, approved for different indications — Mounjaro for type 2 diabetes, Zepbound for chronic weight management¹. Tirzepatide's mechanism is itself distinctive within the class: it's a dual GIP and GLP-1 receptor agonist rather than acting on the GLP-1 receptor alone, which trial data has tied to some of the largest average weight-loss figures reported in this category⁵. As with semaglutide's two brands, dosing and maximum dose can differ slightly between the two labels to fit their respective approved uses.

Compounded tirzepatide: a different regulatory category

Compounded tirzepatide is prepared by a licensed 503A or 503B pharmacy rather than sold as either FDA-approved brand, and — like compounded semaglutide — it is not itself an FDA-approved product². Compounding tirzepatide is generally regarded as more technically complex than compounding semaglutide, which is part of why compounded tirzepatide typically costs more than compounded semaglutide even though both bypass the brand list price. The full vetting checklist that applies to any compounded GLP-1 pharmacy — LegitScript certification, a named pharmacy partner, real clinical screening — is in is compounded semaglutide legit?, and it applies just as much here.

Why compounded tirzepatide exists at scale

Tirzepatide has spent time on the FDA's official drug-shortage list, and shortage status is what gives compounding pharmacies latitude to make copies of a drug in short supply³. As brand-name supply has caught up, that latitude has narrowed, shifting the compounded tirzepatide market toward closer regulatory attention — the same pattern covered fully in GLP-1 shortages and supply and compounded vs brand-name GLP-1, explained.

The price gap, and what drives it

Mounjaro and Zepbound carry high list prices, and insurance coverage for the weight-management indication specifically is inconsistent — our insurance coverage guide breaks down how that coverage actually works and where prior authorization fits in. Compounded tirzepatide is typically much cheaper out of pocket because it isn't priced against a manufacturer list price at all. The full cost comparison across all three paths is in how much does tirzepatide cost. Whether any of these three are even available via telehealth where you live is a separate, state-specific question — see is GLP-1 telehealth legal in my state?.

The safety profile doesn't change

Regardless of which of the three you're on, tirzepatide carries the same FDA-described boxed warning about thyroid C-cell tumors observed in rodent studies and the same contraindication for a personal or family history of medullary thyroid carcinoma or MEN 2¹. Which pharmacy makes your medication changes the regulatory oversight behind it, not the underlying pharmacology or who should avoid the drug.

Making the call

This is a decision for you and a prescriber, weighing cost, access, and your comfort with each product's regulatory status — not a decision to make on price alone. The equivalent semaglutide comparison is in Ozempic vs Wegovy vs compounded semaglutide. Whatever you choose, run any provider through our 5-minute checklist first, and compare how the desks we track score in our provider briefs. This is market and regulatory context, not medical advice.